open access

Vol 92, No 8 (2021)
Review paper
Published online: 2021-08-16
Get Citation

Pertussis vaccination in pregnancy — current data on safety and effectiveness

Monika Zasztowt-Sternicka12, Anna M. Jagielska1, Aneta S. Nitsch-Osuch1
DOI: 10.5603/GP.a2021.0145
·
Pubmed: 34541632
·
Ginekol Pol 2021;92(8):591-594.
Affiliations
  1. Department of Social Medicine and Public Health, Medical University of Warsaw, Poland
  2. Doctoral School Medical University of Warsaw, Poland

open access

Vol 92, No 8 (2021)
REVIEW PAPERS Obstetrics
Published online: 2021-08-16

Abstract

Whooping cough/pertussis is a respiratory infection caused by the bacteria Bordetella pertussis and Bordetella parapertussis. The World Health Organization (WHO) has identified whooping cough as one of the least controlled diseases in all age groups. Clinically, the catarrhal phase manifests itself as flu-like, nonspecific symptoms: cough, runny nose, mild fever, which, regrettably, makes early diagnosis difficult. The severe course is more specific (an audible inspiratory whoop followed by paroxysmal cough and vomiting). Currently, in Poland the highest percentage of cases is observed in children aged 0–4 years, followed by children over 15 years of age, with peaks among teens and seniors. Notably, hospitalization, morbidity and mortality rates are considerable in children (especially infants). Vaccinating pregnant women against pertussis provides approximately 90% protection to infants in their first two months of life. It is an effective form of preventing pertussis in infants. Moreover, it is safe for pregnant women and their children. The Advisory Committee on Immunization Practices (ACIP) recommends Tdap vaccination to every pregnant woman between 27–36 weeks of pregnancy.

Abstract

Whooping cough/pertussis is a respiratory infection caused by the bacteria Bordetella pertussis and Bordetella parapertussis. The World Health Organization (WHO) has identified whooping cough as one of the least controlled diseases in all age groups. Clinically, the catarrhal phase manifests itself as flu-like, nonspecific symptoms: cough, runny nose, mild fever, which, regrettably, makes early diagnosis difficult. The severe course is more specific (an audible inspiratory whoop followed by paroxysmal cough and vomiting). Currently, in Poland the highest percentage of cases is observed in children aged 0–4 years, followed by children over 15 years of age, with peaks among teens and seniors. Notably, hospitalization, morbidity and mortality rates are considerable in children (especially infants). Vaccinating pregnant women against pertussis provides approximately 90% protection to infants in their first two months of life. It is an effective form of preventing pertussis in infants. Moreover, it is safe for pregnant women and their children. The Advisory Committee on Immunization Practices (ACIP) recommends Tdap vaccination to every pregnant woman between 27–36 weeks of pregnancy.

Get Citation

Keywords

effectiveness; pertussis; pregnancy; safety; vaccine

About this article
Title

Pertussis vaccination in pregnancy — current data on safety and effectiveness

Journal

Ginekologia Polska

Issue

Vol 92, No 8 (2021)

Article type

Review paper

Pages

591-594

Published online

2021-08-16

DOI

10.5603/GP.a2021.0145

Pubmed

34541632

Bibliographic record

Ginekol Pol 2021;92(8):591-594.

Keywords

effectiveness
pertussis
pregnancy
safety
vaccine

Authors

Monika Zasztowt-Sternicka
Anna M. Jagielska
Aneta S. Nitsch-Osuch

References (35)
  1. World Health Organization (WHO). Laboratory Manual for the Diagnosis of Whooping Cough caused by Bordetella pertussis/ Bordetella parapertussis, Immunization, Vaccines and Biologicals, Update 2014. www.who.int/vaccines-documents/ (20.10.2020).
  2. Murthy S, Godinho M, Lakiang T, et al. Efficacy and safety of pertussis vaccination in pregnancy to prevent whooping cough in early infancy. Cochrane Database Syst Rev. 2018.
  3. Biuletyny i Meldunki Zakładu Epidemiologii Chorób Zakaźnych i Nadzoru, Pracownia Monitorowania i Analizy Sytuacji Epidemiologicznej. http://wwwold.pzh.gov.pl/oldpage/epimeld/index_p.html (20.10.2020).
  4. World Healt Organization. Pertussis vaccines: WHO position paper – August 2015. Wkly Epidemiol Rec. 2015; 90: 433–460.
  5. European Centre for Disease Prevention and Control. Pertussis In: ECDC. Annual epidemiological report for 2018. Stockholm: ECDC. https://www.ecdc.europa.eu/en/publications-data/pertussis-annual-epidemiological-report-2018 (20.10.2020).
  6. Baxter R, Bartlett J, Fireman B, et al. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics. 2017; 139(5).
  7. Wise J. Whooping cough booster in pregnancy is highly protective for newborns, study finds. BMJ. 2017: j1683.
  8. Van Savage J, Decker MD, Edwards KM, et al. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990; 161(3): 487–492.
  9. Ladhani SN, Andrews NJ, Southern Jo, et al. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clin Infect Dis. 2015; 61(11): 1637–1644.
  10. Quinn HE, Snelling TL, Habig A, et al. Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics. 2014; 134(4): 713–720.
  11. Swamy GK, Wheeler SM. Neonatal pertussis, cocooning and maternal immunization. Expert Rev Vaccines. 2014; 13(9): 1107–1114.
  12. Carcione D, Regan AK, Tracey L, et al. The impact of parental postpartum pertussis vaccination on infection in infants: A population-based study of cocooning in Western Australia. Vaccine. 2015; 33(42): 5654–5661.
  13. Forsyth K, Plotkin S, Tan T, et al. Strategies to decrease pertussis transmission to infants. Pediatrics. 2015; 135(6): e1475–e1482.
  14. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011; 204(4): 334.e1–334.e5.
  15. Gonik B, Puder KS, Gonik N, et al. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol. 2005; 13(2): 59–61.
  16. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004; 190(2): 335–340.
  17. Vygen-Bonnet S, Hellenbrand W, Garbe E, et al. Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review. BMC Infect Dis. 2020; 20(1): 136.
  18. Hoang HaT, Leuridan E, Maertens K, et al. Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. Vaccine. 2016; 34(1): 151–159.
  19. Berenson AB, Hirth JM, Rahman M, et al. Maternal and infant outcomes among women vaccinated against pertussis during pregnancy. Hum Vaccin Immunother. 2016; 12(8): 1965–1971.
  20. Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ. 2014; 349: g4219.
  21. Morgan JL, Baggari SR, McIntire DD, et al. Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet Gynecol. 2015; 125(6): 1433–1438.
  22. Shakib JH, Korgenski K, Sheng X, et al. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr. 2013; 163(5): 1422–6.e1.
  23. Halperin SA, Langley JM, Ye L, et al. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. Clin Infect Dis. 2018; 67(7): 1063–1071.
  24. DeSilva M, Vazquez-Benitez G, Nordin JD, et al. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017; 35(29): 3655–3660.
  25. Griffin JB, Yu L, Watson D, et al. Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine. 2018; 36(34): 5173–5179.
  26. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014; 311(17): 1760–1769.
  27. Maertens K, Caboré RN, Huygen K, et al. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. Vaccine. 2016; 34(1): 142–150.
  28. Becerra-Culqui TA, Getahun D, Chiu V, et al. Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. Pediatrics. 2018; 142(3).
  29. Becerra-Culqui TA, Getahun D, Chiu V, et al. The Association of Prenatal Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccination With Attention-Deficit/Hyperactivity Disorder. Am J Epidemiol. 2020; 189(10): 1163–1172.
  30. Amirthalingam G, Campbell H, Ribeiro S, et al. Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. Clin Infect Dis. 2016; 63(suppl 4): S236–S243.
  31. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014; 384(9953): 1521–1528.
  32. Skoff TH, Blain AE, Watt J, et al. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. Clin Infect Dis. 2017; 65(12): 1977–1983.
  33. Saul N, Wang K, Bag S, et al. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. Vaccine. 2018; 36(14): 1887–1892.
  34. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013; 56(4): 539–544.
  35. Dziennik urzędowy Ministra Zdrowia KOMUNIKAT GŁÓWNEGO INSPEKTORA SANITARNEGO z dnia 16 października 2019 r. w sprawie Programu Szczepień Ochronnych na rok 2020.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl